Stephen J Schuster
University of Pennsylvania · Abramson Cancer Center, University of Pennsylvania
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen J Schuster as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04889716 · CAR-T Followed by Bispecific AntibodiesAbramson Cancer Center at Penn Medicine · active not recruiting · Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma · principal investigator
- Ph1NCT04419909 · Retreatment With CTL019/CTL119University of Pennsylvania · withdrawn · Lymphoma, B-Cell · principal investigator
- Ph1NCT01013441 · CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic LeukemiaUniversity of Pennsylvania · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00783367 · Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasAbramson Cancer Center at Penn Medicine · completed · Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma · principal investigator
- Ph1NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous TransplantUniversity of Pennsylvania · completed · B-cell Lymphoma, Non-Hodgkin's Lymphoma · principal investigator
- Ph3NCT00091676 · Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular LymphomaBiovest International · unknown · Non-Hodgkins Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Models and methods for automatically measuring disease body-wide and staging disease via FDG-PET/CT in LymphomaR01CA255748 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2021 to 2024 · $545,026 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:49 UTC. The ranking covers the 200 most relevant of 69 PubMed records, and a shared surname and initials can bring in a namesake. All 69 on PubMed
- 3,432 citationsRCR 128.5
- PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.N Engl J Med · 20152,951 citationsRCR 86.2
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.N Engl J Med · 20171,540 citationsRCR 46.2
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.N Engl J Med · 20141,382 citationsRCR 39.4
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med · 2014894 citationsRCR 24.0
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.J Clin Oncol · 2016874 citationsRCR 27.2
- 524 citationsRCR 26.6
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.Nat Med · 2022491 citationsRCR 31.6
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J Med · 2022459 citationsRCR 30.2
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.Lancet Oncol · 2022414 citationsRCR 26.0